Disease Markers

Review Article

Clinicopathologic and Prognostic Value of Serum Carbohydrate Antigen 19-9 in Gastric Cancer: A Meta-Analysis

Table 2

Detailed results of subgroup analyses.
 Sample timeCut-offStudy quality
 AnyPreoperative37Other than 37NOS ≥6NOS <6
Stages III/IV versus I/II (OR)3.36 [2.34, 4.84];
3.50 [2.34, 5.23];
3.17 [2.04, 4.94];
3.81 [2.40, 6.06];
2.75 [1.85, 4.10];
4.56 [2.77, 7.50];
pT: T3/T4 versus T1/T2 (OR)2.40 [1.60, 3.59];
2.59 [1.65, 4.07];
2.51 [1.58, 4.00];
2.11 [1.15, 3.88];
2.41 [1.48, 3.94];
2.62 [1.69, 4.07];
Lymph node-positive versus negative (OR)2.91 [2.21, 3.84];
3.15 [2.36, 4.12];
3.07 [2.14, 4.41];
2.29 [1.77, 2.96];
2.47 [1.81, 3.36];
3.62 [2.36, 5.56];
Metastasis-positive versus negative (OR)2.76 [1.12, 6.82];
2.76 [1.12, 6.82];
////
Peritoneal dissemination positive versus negative (OR)2.20 [1.25, 3.90];
2.55 [1.35, 4.83];
2.18 [0.95, 4.99];
2.23 [1.03, 4.83];
1.43 [0.68, 3.05];
2.98 [1.59, 5.59];
Hepatic metastasis-positive versus negative (OR)3.13 [1.50, 6.55];
3.82 [1.98, 7.36];
3.27 [1.40, 7.65];
3.13 [0.83, 11.82];
1.71 [0.34, 8.68];
4.01 [1.61, 9.99];
Lauren type: diffuse versus intestinal (OR)0.89 [0.62, 1.27];
0.89 [0.62, 1.27];
0.78 [0.47, 1.27];
1.04 [0.62, 1.76];
0.83 [0.53, 1.29];
1.02 [0.55, 1.90];
Differentiated: poor versus well + moderate (OR)0.87 [0.72, 1.04];
0.85 [0.70, 1.03];
0.87 [0.72, 1.06];
0.86 [0.49, 1.50];
0.74 [0.57, 0.98];
0.99 [0.77, 1.27];
Vessel invasion-positive versus negative (OR)1.66 [1.11, 2.48];
2.24 [1.09, 4.60];
/1.99 [1.11, 3.55];
1.68 [1.03, 2.73];
1.64 [0.81, 3.30];
Lymphatic invasion-positive versus negative (OR)1.44 [0.91, 2.28];
1.20 [0.57, 2.51];
1.36 [0.82, 2.25];
/1.36 [0.82, 2.25];
/
OS (HR)1.83 [1.56, 2.15];
1.87 [1.52, 2.30];
1.87 [1.53, 2.30];
1.78 [1.30, 2.43];
1.72 [1.47, 2.01];
1.99 [1.31, 3.04];
DFS (HR)1.85 [1.16, 2.95];
1.96 [1.00, 3.85];
1.55 [1.15, 2.08];
3.15 [0.68, 14.63];
1.54 [1.16, 2.03];
/
DSS (HR)1.33 [1.10, 1.60];
1.33 [1.10, 1.60];
1.36 [1.12, 1.65];
/1.33 [1.10, 1.60];
/
Note. DFS: disease-free survival; DSS: disease-specific survival; HR: hazard ratio; NOS: Newcastle-Ottawa Scale; OR: odds ratio; OS: overall survival; “/” symbol: no results due to insufficient studies.
Subgroup analysis was stratified by sample time. “Any” means including preoperative and postoperative sample time. “Preoperative” means including preoperative sample time only.
Subgroup analysis was stratified by cut-off value: 37 U/mL and other than 37 U/mL.
Subgroup analysis was stratified by study quality: NOS ≥6 and NOS <6.
OR was used as effect measure to assess the result of carbohydrate antigen 19-9 detection in different clinicopathologic characteristics.
The result was presented together with its 95% confidence intervals (in square brackets). Furthermore, statistics in the pooled analyses were presented.
HR was used as effect measure to assess the relationship between carbohydrate antigen 19-9 and prognosis.